CA2409059C - Stabilized aqueous suspensions for parenteral use - Google Patents
Stabilized aqueous suspensions for parenteral use Download PDFInfo
- Publication number
- CA2409059C CA2409059C CA002409059A CA2409059A CA2409059C CA 2409059 C CA2409059 C CA 2409059C CA 002409059 A CA002409059 A CA 002409059A CA 2409059 A CA2409059 A CA 2409059A CA 2409059 C CA2409059 C CA 2409059C
- Authority
- CA
- Canada
- Prior art keywords
- formulation according
- formulation
- methionine
- biologically active
- steroidal compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of L-Methionine. Preferably, the biologically active compound is a steroidal compound, for instance exemestane, medroxyprogesterone acetate and estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.
Description
STABILIZED AQUEOUS SUSPENSIONS FOR PARENTERAL USE
Summary of the invention The present invention is in the field of galenic preparations. It concerns in particular a pharmaceutical aqueous suspension of a biologically active compound, e.g. a steroidal compound, having stabilized pH, particularly suitable for parenteral administration.
The inventors of the present invention have found that the pH of a pharmaceutical aqueous suspension of a biologically active compound can be controlled by adding a to pH controlling effective concentration of L-Methionine thereto.
Moreover, when a pH controlling effective concentration of L-Methionine is used, it strengthens the buffering capacity of low concentrations of conventional buffering agents with a super-additive (synergistic) effect. In this way the use of conventional buffering agents can be eliminated or limited, thus improving the re-suspendability and controlled flocculation of the pharmaceutical preparation.
Background of the invention A pharmaceutical suspension is a coarse dispersion in which insoluble solid particles are dispersed in a liquid medium.
Suspensions contribute to pharmacy and medicine by supplying insoluble and often distasteful substances in a form that is pleasant to the taste, by providing a suitable form for the application of dermatological materials to the skin and sometimes to the mucous membranes, and for the parenteral administration of insoluble drugs.
Therefore pharmaceutical suspensions may be classified into three groups: orally administered mixtures, externally applied lotions and injectable preparations.
An acceptable suspension possesses certain desirable qualities, including the followings:
i) the suspended material should not settle rapidly;
ii) the particles that do settle to the bottom of the container must not form a hard cake 3o but should be readily re-dispersed into a uniform mixture when the container is shaken;
Summary of the invention The present invention is in the field of galenic preparations. It concerns in particular a pharmaceutical aqueous suspension of a biologically active compound, e.g. a steroidal compound, having stabilized pH, particularly suitable for parenteral administration.
The inventors of the present invention have found that the pH of a pharmaceutical aqueous suspension of a biologically active compound can be controlled by adding a to pH controlling effective concentration of L-Methionine thereto.
Moreover, when a pH controlling effective concentration of L-Methionine is used, it strengthens the buffering capacity of low concentrations of conventional buffering agents with a super-additive (synergistic) effect. In this way the use of conventional buffering agents can be eliminated or limited, thus improving the re-suspendability and controlled flocculation of the pharmaceutical preparation.
Background of the invention A pharmaceutical suspension is a coarse dispersion in which insoluble solid particles are dispersed in a liquid medium.
Suspensions contribute to pharmacy and medicine by supplying insoluble and often distasteful substances in a form that is pleasant to the taste, by providing a suitable form for the application of dermatological materials to the skin and sometimes to the mucous membranes, and for the parenteral administration of insoluble drugs.
Therefore pharmaceutical suspensions may be classified into three groups: orally administered mixtures, externally applied lotions and injectable preparations.
An acceptable suspension possesses certain desirable qualities, including the followings:
i) the suspended material should not settle rapidly;
ii) the particles that do settle to the bottom of the container must not form a hard cake 3o but should be readily re-dispersed into a uniform mixture when the container is shaken;
iii) the suspension must not be too viscous to pour freely from the orifice of the bottle or to flow through a syringe needle.
It is important that the characteristics of the dispersed phase are chosen with care so to as to produce a suspension having optimum physical, chemical and pharmacological properties. Particle size distribution, specific surface area, inhibition of crystal growth, and changes in the polymorphic form are of special significance and the formulator must ensure that these and other properties do not change sufficiently during storage to adversely affect the performance of the suspensions with aging.
In the field of injectable preparations, aqueous suspensions -for---parenteral , administration have already been described in scientific and patent literature and have been known for a long time. Parenteral suspensions are often prepared with the so called "controlled flocculation" approach, i.e. by the application of known principles of formulation chemistry to produce vehicles which permits drug flocs to form and settle, but which they are easily re-suspended with slight agitation and remain uniformly dispersed or suspended during the period required for therapeutic administration.
Specifically, it is well known that one of the main difficulty in formulating parenteral aqueous suspensions of steroids is the overcome of their hydrophobicity, that significantly reduce the wettability, suspendability or re-suspendibility of the active in aqueous media. Both wetting and suspending agents are needed in order to gain the 2o proper formulation of the active compound such as the concomitant use of preservatives. This is described, for example, by Nash and coworkers in the US
Patent 3,457,348 where non-ionic surfactants (such as polysorbates) and suspending agents (like polyethylene glycols) are the basic excipients to gain the proper stability of the formulation.
Sometimes, even in the presence of the proper suspending and wetting agents, the suspension is not stable for a long time, but it is necessary to form it just before the administration (while it is stored as lyophilized formulation). This is described, for example, in the case described by Geller and coworkers in the US Patent 5,002,940 and greatly impacts on the cost of the manufacturing process, since an additional freeze 3o drying process is mandatory.
Even if an improved physical stability of steroidal drug suspensions in water can be gained, as above mentioned, by the use of polyethylene glycols and non-ionic surfactants, some chemical stability issues, such as a relevant pH reduction, are likely to be faced during development.
In fact, for instance, both polyethylene glycols and polysorbates, when in solution, may undergo degradation, leading to the formation of acid species such as formic and acetic acid.
An example of this pH reduction effect is given in Table 1.
l0 Table 1: pH of a typical vehicle for parenteral aqueous suspensions formulations Vehicle composition (batch 13169/12-lA): Methylparaben 0.2%, propylparaben 0.02%, sodium chloride 0.9%, PEG 4000 3%, polysorbate 80 0.3%, sodium hydroxide q.s. to pH 6.5 , WFI q.s to 100 ml.
Storage conditionPH
Time zero 6.46 da s at 65C 3.43 da s at 65C 3.16 1 month at 65C 3.32 3 months at 40C 3.24 6 months at 40C 3.15 6 months at 25C 4.93 15 This pH reduction occurs both at accelerated testing conditions and at room temperature. Considering that after only 6 months at .room temperature a relevant decrease of approximately 1.5 pH unit is experimented, very low pH values (close or below 3) are anticipated after long-term storage (1 - 2 years). This fact necessarily causes the reduced shelf life of parenteral suspension, being the progressive acidification of the formulation linked to the impossibility to administer the formulation, e.g. by intramuscular or subcutaneous injection, without generating significant pain on patients (it is advisable that the pH value is maintained above 3 for administering a painless formulation).
It is important that the characteristics of the dispersed phase are chosen with care so to as to produce a suspension having optimum physical, chemical and pharmacological properties. Particle size distribution, specific surface area, inhibition of crystal growth, and changes in the polymorphic form are of special significance and the formulator must ensure that these and other properties do not change sufficiently during storage to adversely affect the performance of the suspensions with aging.
In the field of injectable preparations, aqueous suspensions -for---parenteral , administration have already been described in scientific and patent literature and have been known for a long time. Parenteral suspensions are often prepared with the so called "controlled flocculation" approach, i.e. by the application of known principles of formulation chemistry to produce vehicles which permits drug flocs to form and settle, but which they are easily re-suspended with slight agitation and remain uniformly dispersed or suspended during the period required for therapeutic administration.
Specifically, it is well known that one of the main difficulty in formulating parenteral aqueous suspensions of steroids is the overcome of their hydrophobicity, that significantly reduce the wettability, suspendability or re-suspendibility of the active in aqueous media. Both wetting and suspending agents are needed in order to gain the 2o proper formulation of the active compound such as the concomitant use of preservatives. This is described, for example, by Nash and coworkers in the US
Patent 3,457,348 where non-ionic surfactants (such as polysorbates) and suspending agents (like polyethylene glycols) are the basic excipients to gain the proper stability of the formulation.
Sometimes, even in the presence of the proper suspending and wetting agents, the suspension is not stable for a long time, but it is necessary to form it just before the administration (while it is stored as lyophilized formulation). This is described, for example, in the case described by Geller and coworkers in the US Patent 5,002,940 and greatly impacts on the cost of the manufacturing process, since an additional freeze 3o drying process is mandatory.
Even if an improved physical stability of steroidal drug suspensions in water can be gained, as above mentioned, by the use of polyethylene glycols and non-ionic surfactants, some chemical stability issues, such as a relevant pH reduction, are likely to be faced during development.
In fact, for instance, both polyethylene glycols and polysorbates, when in solution, may undergo degradation, leading to the formation of acid species such as formic and acetic acid.
An example of this pH reduction effect is given in Table 1.
l0 Table 1: pH of a typical vehicle for parenteral aqueous suspensions formulations Vehicle composition (batch 13169/12-lA): Methylparaben 0.2%, propylparaben 0.02%, sodium chloride 0.9%, PEG 4000 3%, polysorbate 80 0.3%, sodium hydroxide q.s. to pH 6.5 , WFI q.s to 100 ml.
Storage conditionPH
Time zero 6.46 da s at 65C 3.43 da s at 65C 3.16 1 month at 65C 3.32 3 months at 40C 3.24 6 months at 40C 3.15 6 months at 25C 4.93 15 This pH reduction occurs both at accelerated testing conditions and at room temperature. Considering that after only 6 months at .room temperature a relevant decrease of approximately 1.5 pH unit is experimented, very low pH values (close or below 3) are anticipated after long-term storage (1 - 2 years). This fact necessarily causes the reduced shelf life of parenteral suspension, being the progressive acidification of the formulation linked to the impossibility to administer the formulation, e.g. by intramuscular or subcutaneous injection, without generating significant pain on patients (it is advisable that the pH value is maintained above 3 for administering a painless formulation).
This pH variation during storage can be minimized by appropriately buffering the formulation. The most obvious approach, in order to maintain the pH within specific and predetermined limits, is the use of buffering agents, such as inorganic acid salts, in appropriate concentrations in order not only to exert but also to maintain their buffering capacity. An example of buffering agents commonly used in parenteral formulations and of their usual concentrations can be found in Pharmaceutical Dosage Form: Parenteral Medications, Volume 1, 2°d Edition, Chapter 5, p. 194, De Luca and Boylan, "Formulation of Small Volume Parenterals", Table 5: Commonly used additives in Parenteral Products.
The use of inorganic acid salts as buffering agents offers to the formulator both advantages and disadvantages. In fact, if a careful control of pH of formulations could be gained, on the contrary, when suspension formulations are concerned, ionic species tend to destabilize the formulations with detrimental effects on the re-suspendability and on the controlled flocculation of the formulation. This means that the use of inorganic acid salt based buffering systems into the formulations has to be minimized.
In fact, when talking about parenteral suspension, according to Nash (Parenteral Suspensions, Bulletin of Parenteral Drug Association, March-April 1972, Vol.
26, No.
2), "... indiscriminate use of salts and buffers is normally avoided, provided chemical stability is not a problem since changes in electrolyte concentration often have a profound effect on the absorbed surface charge of suspension particles".
An example of the relevant pH decrease occurring in a medroxyprogesterone acetate parenteral aqueous suspension is showed in Table 2. This accelerated stability study shows that the pH of an unbuffered formulation significantly decrease from an initial pH value of approx. 6.5 to pH values of 3 or lower than 3. It also demonstrates that , when a usual concentration (approx. 1%) of phosphate buffer is added to control the pH, a detrimental effect on the suspension re-suspendability and syringeability is experimented. In fact an increased time of manual wrist shaking is needed to re-suspend the buffered suspension after 1 month at 55°C vs. the unbuffered one. Besides, after 2 month at 55°C the buffered suspension cannot be re-suspended at all by manual 3o wrist shaking and, as a consequence, cannot be administered. On the other hand, when a lower and unusual concentration (approx. 0.1%) of phosphate buffer is used, no relevant effect on suspension re-suspendability is experimented but, at the same time, no substantial pH control is obtained.
Table 2: pH, re-suspendability and syringeability study of "buffered" vs. "as is"
The use of inorganic acid salts as buffering agents offers to the formulator both advantages and disadvantages. In fact, if a careful control of pH of formulations could be gained, on the contrary, when suspension formulations are concerned, ionic species tend to destabilize the formulations with detrimental effects on the re-suspendability and on the controlled flocculation of the formulation. This means that the use of inorganic acid salt based buffering systems into the formulations has to be minimized.
In fact, when talking about parenteral suspension, according to Nash (Parenteral Suspensions, Bulletin of Parenteral Drug Association, March-April 1972, Vol.
26, No.
2), "... indiscriminate use of salts and buffers is normally avoided, provided chemical stability is not a problem since changes in electrolyte concentration often have a profound effect on the absorbed surface charge of suspension particles".
An example of the relevant pH decrease occurring in a medroxyprogesterone acetate parenteral aqueous suspension is showed in Table 2. This accelerated stability study shows that the pH of an unbuffered formulation significantly decrease from an initial pH value of approx. 6.5 to pH values of 3 or lower than 3. It also demonstrates that , when a usual concentration (approx. 1%) of phosphate buffer is added to control the pH, a detrimental effect on the suspension re-suspendability and syringeability is experimented. In fact an increased time of manual wrist shaking is needed to re-suspend the buffered suspension after 1 month at 55°C vs. the unbuffered one. Besides, after 2 month at 55°C the buffered suspension cannot be re-suspended at all by manual 3o wrist shaking and, as a consequence, cannot be administered. On the other hand, when a lower and unusual concentration (approx. 0.1%) of phosphate buffer is used, no relevant effect on suspension re-suspendability is experimented but, at the same time, no substantial pH control is obtained.
Table 2: pH, re-suspendability and syringeability study of "buffered" vs. "as is"
5 20% Medroxy ProgesteroneAcetate parenteral aqueous suspension formulations Suspension composition (batch 13451/01-1): Medroxyprogesterone acetate 20%, MyristylGammaPicoliniumChloride 0.2%, sodium sulphate 1.1%, PEG 3350 2.03%, sodium hydroxide q.s. to pH 6.5 , WFI q.s to 100 ml.
Batch 13451/01-1 A: as B: C:
is + Phosphate Phosphate buffer buffer ~
1%
0.1%
pH Syring.pH Resusp.Syring.PH Resusp.Syring.
Time 6.35 R MT 6.71 R MT 6.30R MT
zero (T (T= (T=lOs) = 8s) 7s) 1 month3.12 R MT 3.67 R MT 5.94R MT
at 55C (T (T =29s) (T
=18s) =40s) 2 months2.92 R MT 3.28 R MT 5.93NR NP
at (T (T=
55C =33s) 24s) 3 months2.83 R MT 3.15 R MT 5.81NR NP
at (T (T=
55C =31s) 32s) Phosphate Buffers (M = Concentration Concentration molar) ~ 0.1 % ~ 1 %
Monobasic Sodium Phosphate.lmg 69.4 l 100 mg 694 / 100 H20 (MW ml ml 137.99) (0.005 M) (0.05 M) Dibasic Sodium Phosphate. mg 58.8 / 100 mg 588 / 100 l2 H20 (MW ml ml 358.14) (0.0016 M) (0.016 M) Resuspendability R= RESUSPENDABLE by manual wrist shaking. In brackets: T= time of manual wrist shaking requested in order to obtain a homogeneous suspension (s=seconds).
NR= NOT RESUSPENDABLE
Syringeability MT= meets test NP= not performed as product cannot be resuspended and therefore cannot be homogeneously withdrawed and syringed Description of the invention 2o The inventors of the present invention have surprisingly found out that suitable concentrations of L-Methionine are able both to control the pH of a pharmaceutical aqueous suspension of a biologically active compound, in particular a steroidal compound, by minimizing its pH decrease and to strengthen the pH controlling capacity of lower and unusual concentrations of conventional buffering agents, with a super-additive (synergistic) effect.
In fact the gist of the present invention is based on the finding that an oxygen scavenger such as L-Methionine not only shows antioxidant properties per se, like known anti-oxidant thiol-derivatives, but surprisingly itself takes part in pH
controlling activity.
A first object of the present invention is thus to provide the use of L-Methionine as pH
controlling agent in a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biohgieally active to compound.
A further object of the present invention is to provide a pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH
comprising a biologically active compound and a pH controlling effective concentration of L-Methionine.
Object of the invention is also the use of L-Methionine, in a pH controlling effective concentration, in the preparation of a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biologically active compound.
A further object is a method for preparing a pharmaceutical aqueous suspension 2o formulation for parenteral administration of a biologically active compound having substantially stabilized pH, characterized in that a pH controlling effective concentration of L-Methionine is added thereto.
The inventors have also found that L-Methionine, besides exercising a pH
controlling activity per se, also strengthens the pH controlling capacity of a conventional buffer with a (super-additive) synergistic effect.
A super-additive (synergistic) effect is a pH controlling effect that is greater than the one which is expected to be obtainable by summing up the experimentally verified pH
controlling effects of the single agents.
This means that low unusual concentrations of conventional buffering agents can be 3o included into the formulations, without any risk of loosing in buffering capacity and, at the same time, to deteriorate the physico-technological quality of parenteral suspensions.
A further advantage is given by the fact that as no relevant concentrations of buffers are needed, the formulation has low or no buffering capacity per se and therefore, once administered, the pH of the formulation will be easily adjusted to the physiological value by the buffering capacity of body fluids.
As stated above, the reduction in the quantity of conventional buffering agents, such as inorganic acid salts, improves the physical stability of the formulation, since ionic species tend to destabilize the formulations with detrimental effeets -on the re-to suspendibility and on the controlled flocculation of the formulation.
A further object of the invention is therefore to provide a pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH
comprising a biologically active compound, a buffering agent and L-Methionine in concentrations effective to produce a pH controlling super-additive effect.
The present invention also provides the combined use of L-Methionine and a conventional buffering agent in concentrations effective to produce a pH
controlling super-additive effect, in the preparation of a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biologically active compound.
2o The term "a buffering agent" is herein meant to comprise (unless otherwise specified) both a single buffering agent~and a mixture of two or more thereof.
The term "substantially pH stabilized" means that the pH of the formulation remains within acceptable limits for parenteral administration over the time, according to well known practice in the art. It also means that the pH of the formulation containing L-Methionine, or the combination of L-Methionine and a buffering agent in concentrations effective to provide a pH controlling super-additive effect, is maintained over the time closer to the initial value than the pH of the "as is"
formulation (i.e. the formulation without L-Methionine or the combination of L-Methionine and a buffering agent).
3o The pH range for the suspension formulation of the invention is from about pH 3.0 to about pH 8.0, preferably pH 3.0 to pH 7.5, and most preferably pH 4.0 to pH
7Ø
Batch 13451/01-1 A: as B: C:
is + Phosphate Phosphate buffer buffer ~
1%
0.1%
pH Syring.pH Resusp.Syring.PH Resusp.Syring.
Time 6.35 R MT 6.71 R MT 6.30R MT
zero (T (T= (T=lOs) = 8s) 7s) 1 month3.12 R MT 3.67 R MT 5.94R MT
at 55C (T (T =29s) (T
=18s) =40s) 2 months2.92 R MT 3.28 R MT 5.93NR NP
at (T (T=
55C =33s) 24s) 3 months2.83 R MT 3.15 R MT 5.81NR NP
at (T (T=
55C =31s) 32s) Phosphate Buffers (M = Concentration Concentration molar) ~ 0.1 % ~ 1 %
Monobasic Sodium Phosphate.lmg 69.4 l 100 mg 694 / 100 H20 (MW ml ml 137.99) (0.005 M) (0.05 M) Dibasic Sodium Phosphate. mg 58.8 / 100 mg 588 / 100 l2 H20 (MW ml ml 358.14) (0.0016 M) (0.016 M) Resuspendability R= RESUSPENDABLE by manual wrist shaking. In brackets: T= time of manual wrist shaking requested in order to obtain a homogeneous suspension (s=seconds).
NR= NOT RESUSPENDABLE
Syringeability MT= meets test NP= not performed as product cannot be resuspended and therefore cannot be homogeneously withdrawed and syringed Description of the invention 2o The inventors of the present invention have surprisingly found out that suitable concentrations of L-Methionine are able both to control the pH of a pharmaceutical aqueous suspension of a biologically active compound, in particular a steroidal compound, by minimizing its pH decrease and to strengthen the pH controlling capacity of lower and unusual concentrations of conventional buffering agents, with a super-additive (synergistic) effect.
In fact the gist of the present invention is based on the finding that an oxygen scavenger such as L-Methionine not only shows antioxidant properties per se, like known anti-oxidant thiol-derivatives, but surprisingly itself takes part in pH
controlling activity.
A first object of the present invention is thus to provide the use of L-Methionine as pH
controlling agent in a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biohgieally active to compound.
A further object of the present invention is to provide a pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH
comprising a biologically active compound and a pH controlling effective concentration of L-Methionine.
Object of the invention is also the use of L-Methionine, in a pH controlling effective concentration, in the preparation of a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biologically active compound.
A further object is a method for preparing a pharmaceutical aqueous suspension 2o formulation for parenteral administration of a biologically active compound having substantially stabilized pH, characterized in that a pH controlling effective concentration of L-Methionine is added thereto.
The inventors have also found that L-Methionine, besides exercising a pH
controlling activity per se, also strengthens the pH controlling capacity of a conventional buffer with a (super-additive) synergistic effect.
A super-additive (synergistic) effect is a pH controlling effect that is greater than the one which is expected to be obtainable by summing up the experimentally verified pH
controlling effects of the single agents.
This means that low unusual concentrations of conventional buffering agents can be 3o included into the formulations, without any risk of loosing in buffering capacity and, at the same time, to deteriorate the physico-technological quality of parenteral suspensions.
A further advantage is given by the fact that as no relevant concentrations of buffers are needed, the formulation has low or no buffering capacity per se and therefore, once administered, the pH of the formulation will be easily adjusted to the physiological value by the buffering capacity of body fluids.
As stated above, the reduction in the quantity of conventional buffering agents, such as inorganic acid salts, improves the physical stability of the formulation, since ionic species tend to destabilize the formulations with detrimental effeets -on the re-to suspendibility and on the controlled flocculation of the formulation.
A further object of the invention is therefore to provide a pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH
comprising a biologically active compound, a buffering agent and L-Methionine in concentrations effective to produce a pH controlling super-additive effect.
The present invention also provides the combined use of L-Methionine and a conventional buffering agent in concentrations effective to produce a pH
controlling super-additive effect, in the preparation of a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biologically active compound.
2o The term "a buffering agent" is herein meant to comprise (unless otherwise specified) both a single buffering agent~and a mixture of two or more thereof.
The term "substantially pH stabilized" means that the pH of the formulation remains within acceptable limits for parenteral administration over the time, according to well known practice in the art. It also means that the pH of the formulation containing L-Methionine, or the combination of L-Methionine and a buffering agent in concentrations effective to provide a pH controlling super-additive effect, is maintained over the time closer to the initial value than the pH of the "as is"
formulation (i.e. the formulation without L-Methionine or the combination of L-Methionine and a buffering agent).
3o The pH range for the suspension formulation of the invention is from about pH 3.0 to about pH 8.0, preferably pH 3.0 to pH 7.5, and most preferably pH 4.0 to pH
7Ø
A pH controlling effective concentration of L-Methionine, when used as a single pH
controlling agent, may vary from about 0.005% w/v to about 5% w/v, preferably from about 0.01% w/v to about 1.0% w/v.
The pH controlling effective concentration of L-Methionine, when used as a combined pH controlling agent, may be substantially the same as above.
Thanks to the pH controlling properties of L-Methionine and the superadditive pH
controlling effect, which is obtainable by using L-Methionine in combination with a conventional buffering agent, the concentration of the latter can be reduced by about 50% to about 95%. Namely the concentration of the buffering agent-~an-thus range to from about 5% to about 50% of the usual buffering concentration thereof, preferably from about 5 % to about 25 %.
The usual concentrations of conventional buffering agents employed in parenteral formulations can be found in: Pharmaceutical Dosage Form: Parenteral Medications, Volume 1, 2°d Edition, Chapter 5, p. 194, De Luca and Boylan, "Formulation of Small Volume Parenterals", Table 5: Commonly used additives in Parenteral Products.
According to said literature, the usual buffering concentration for phosphoric acid salts range from about 0.8% to about 2.Oalo w/v or w/w. On the contrary, thanks to the newly found super-additive effect, the concentration of phosphoric acid salts according to the formulation of the invention are lower than 0.4% w/w or w/v, preferably lower than 0.2% w/w or w/v.
Re-suspendibility and controlled flocculation of the pharmaceutical aqueous suspension are thus improved.
The pharmaceutical aqueous suspension, according to the invention, may in addition also include one or more surfactants, suspending agents and/or thickening agents.
Suitable surfactants are for instance phospholipids (e.g. lecithin), cationic surfactants (e.g. myristylgammapicolinium chloride), anionic surfactants and non-ionic surfactants (e.g. polysorbate 80).
Suitable suspending andlor density adjusting agents are for instance polyvinylpyrrolidone compounds and polyethylene glycols. Preferred examples of 3o polyethylene glycols are those having a molecular weight from about 300 to about 6000, e.g. polyethylene glycol 3350 and polyethylene glycol 4000. Preferred polyvinylpyrrolidone (PVP) compounds according to the invention are those having a molecular weight from about 7000 to about 54000, for instance PVP K12, K17, and K30, in particular K12 and K17, PVP K17 being the most preferred.
According to a preferred embodiment of the invention, the pharmaceutical aqueous suspension formulation of the invention in addition contain a suitable amount of a PVP
compound, in particular K12 or K17, especially K17.
Suitable thickening or viscosity agents are for instance well known cellulose derivatives (e.g. methylcellulose, carboxymethylcellulose, hydroxyethylcellulose and hydroxypropylmethylcellulose), gelatin and acacia, in particular methyleellui~ose.
In addition, the formulations of the present invention may also include metal chelating agents, antioxidants or thiol-containing compounds and preservatives.
Suitable metal chelating agents are for instance ethylenediamine-tetracetic acid salts (e.g. edetate disodium).
Suitable antioxidants are for instance ascorbic acid derivatives (e.g.
ascorbic acid, erythorbic acid, sodium ascorbate), thiol derivatives (e.g. thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, dithiothreitol, gluthathione), tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, sulfurous acid salts (e.g.
sodium sulfate, sodium bisulfite, acetone sodium bisulfite, sodium metabisulfite, sodium sulfite, sodium formaldehyde sulfoxylate, sodium thiosulfate) and 2o nordihydroguaiareticacid.
Suitable preservatives are for instance phenol, chlorobutanol, benzylalcohol, methyl paraben, propyl paraben, benzalkonium chloride and cetylpyridinium chloride.
In addition; the formulations of the present invention may also include tonicity adjusting agents. Suitable tonicity adjusting agents are for instance sodium chloride, sodium sulfate, dextrose, mannitol and glycerol.
The formulations of the present invention may also have a nitrogen blanket,overlay on the head-space of the vial. Additionally, the formulations of the present invention may include purging the formulation buffer with helium, argon, or nitrogen.
When the formulation of the invention, besides L-Methionine, contains also buffering 3o agents, useful buffers include e.g. those derived from acetic, aconitic, citric, glutaric, lactic, malic, succinic, phosphate and carbonic acids, as known in the art.
Typically employed is an alkali or alkaline earth salt of one of the aforementioned acids.
Phosphate and citrate buffers, such as phosphoric acid or a pharmaceutically acceptable salt thereof, or citric acid or a pharmaceutically acceptable salt thereof, are preferred.
Sodium phosphate or sodium citrate is the preferred buffering agents, with sodium 5 phosphate being most preferred.
The pharmaceutical aqueous suspension according to the invention is e.g. for intramuscular, subcutaneous and intradermal administration, preferably for intramuscular and subcutaneous administration.
A biological active compound according to the invention is any compound that after l0 administration to a mammal, including humans, provides a therapeutic effect.
Preferably it is a steroidal biologically active compound.
A steroidal biologically active compound according to the invention is the steroidal compound itself or, when appropriate, a pharmaceutically acceptable salt thereof as known in the art, e.g. medroxyprogesterone acetate, exemestane, estradiol cypionate, methylprednisolone acetate, oxabolone cypionate, clostebol acetate, testosterone cypionate; preferably medroxyprogesterone acetate, estradiol cypionate and exemestane, or a combination of two or more thereof according to the art.
Concentrations of medroxyprogesterone acetate in the formulation can range from about 1% w/v to about 40% w/v, preferably from about 3% w/v to about 30% w/v.
2o Concentrations of estradiol cypionate in the formulation can range from about 0.1%
wlv to about 5% w/v, preferably from about 0.25% w/v to about 2.5 % w/v.
When a combination of estradiol cypionate and medroxyprogesterone acetate is the active ingredient of the pharmaceutical preparation of the invention, the amounts of such compounds present in the pharmaceutical preparation are substantially as here above.
Concentrations of exemestane in the formulation can range from about 1% wlv to about 25% w/v, preferably from about 5% wlv to about 20% w/v.
The steroidal biologically active compound is preferably in milled or micronized form according to the common practice.
3o The pH controlling activity of L-Methionine either alone or in combination with a conventional buffer is shown for instance by the following examples.
Example 1 pH stabilization of a parenteral aqueous suspension of Exemestane (CAS: 6-Methylenandrosta-1,4-dime-3,17-dione; other name: Androsta-1,4-dime-3,17-dione-methylene) by means of L-Methionine.
Exemestane is an irreversible aromatase inhibitor, structurally related to the natural steroid androstenedione and it is a molecule prone to oxidation. When performing an experimental study, by adding different antioxidants to a IO% Exemestane parenteral aqueous suspension we have surprisingly found out that L-Methionine can stabilize the pH of the suspension. In fact, the experimental data provided in Taabl~ 3 clearly to demonstrate that in the suspension formulation containing L-Methionine the pH
reduction is minimized in comparison with the "as is" and that by adding L-Methionine, the pH of the suspension is stabilized at values above pH 4.5 even after 2 months storage at 55°C.
What is outmost surprising is that among the added antioxidants, only Methionine is effective in substantially controlling/stabilizing the pH of the suspension (after 2 months storage at 55°C the pH decrease of the formulations containing ascorbic acid, and sodium metabisulfite is in fact comparable or worse than the one experimented in the "as is" formulation).
Therefore a simple antioxidant effect cannot explain the result obtained and the 2o presence of a specific stabilizer, such as L-Methionine, is needed in order to prevent a dramatic pH decrease and stabilize the parenteral aqueous suspension.
The present invention, however, is not intended to be limited to any particular theory of the exact mechanism of this substantial pH stabilization but relates to the fact that a substantial pH stabilization is obtained, to the unconventional way through which this substantial pH stabilization is obtained and to its possible advantages.
It is an advantage of the present invention that the pH of these stabilized parenteral aqueous suspensions does not dramatically decrease during storage but, on the contrary, is maintained closer to the initial value (i.e. closer to neutrality) and therefore these stabilized suspensions can be safely administered without generating significant pain on patients.
Table 3: pH study of a 10% Exemestane parenteral aqueous suspension formulation containing different antioxidants.
Suspension composition (batch 13833/11): Exemestane 10%, methylparaben 0.18%, propylparaben 0.02%, sodium chloride 0.9%, PEG 4000 3.0%, polysorbate 80 0.2%, sodium hydroxide q.s. to pH 6.0 - 6.5 , WFI q.s to 100 ml.
A: as is B: + D: E:
Ascorbic+ Sodium -1- L-Methionine Acid Metabisulfite Time zero 6.02 6.40 6.47 6.00 1 month 4.28 4.20 2.30 4 at .86 55C __ v 2 months 4.03 4.18 2.50 4.74 at Example 2 pH and technological quality (re-suspendability, syringeability) stabilization of a medroxyprogesterone acetate parenteral aqueous suspension by means of L-Methionine 1o used alone or in combination with low and unconventional concentrations of phosphate buffer.
As previously shown in Table 2, the use of a conventional buffering agent, such as Phosphate buffer, in usual effective concentrations (approx. 1%) in order to stabilize the pH of a medroxyprogesterone acetate aqueous suspension has a detrimental effect on the suspension technological quality, i.e. resuspendability and syringeability.
In this example, outlined in Table 4 (Tables 4a and 4b), it is evident that the pH of the same type of suspension can be controlled/stabilized by using L-Methionine alone or by a combination of L-Methionine with a lower and unusual concentration of phosphate buffer (approx. 0.1 %). In fact, when L-Methionine is used alone, as in the 2o case of batch 13451/47-I, a substantially stabilized pH is obtained.
Besides, when L-Methionine is used in combination with a low unusual concentration of Phosphate buffer (approx. 0.1%) a synergistic effect is obtained.
In fact, as clearly shown in the case of batch 13451/47-C, when an unusually low concentration of phosphate buffer (approx. 0.1%) is used, no significant pH
stabilization is obtained vs. the "as is" formulation.
On the contrary, when the same low unusual concentration of phosphate buffer (approx. 0.1%) is used in combination with L-Methionine, as in the case of batch 13451/84-D, a surprising super-additive effect is obtained in controlling/stabilizing the pH of the formulation.
Besides, when L-Methionine is used alone or in combination with a low unusual amount of phosphate buffer, no negative effect is produced on the suspension's technological quality, thus allowing the achievement of a pH stabilized medroxyprogesterone acetate suspension with good re-suspendability and syringeability properties that are maintained during storage. ~ w-On the contrary, when a usual effective concentration of phosphate buffer (approx. 1%) is used in order to stabilize the pH, as in the case of batch 13451/47-G, a detrimental effect on the physical stability of the formulation is obtained.
It is an advantage of this invention that the pH of parenteral aqueous suspensions can be substantially stabilized without using effective usual concentrations of conventional buffering agents, i.e. typically inorganic or organic acid salts, thus avoiding some substantial drawbacks, such as the profound effects caused by ionic species, and especially by polyvalent ions, on the nature and the stability of flocculated suspensions, with detrimental effects on suspension re-suspendability and syringeability.
Table 4: pH, resuspendability and syringeability study of a 20%
Medroxyprogesterone Acetate (MPA) parenteral aqueous suspension formulated with different amounts of L-Methionine and Phosphate buffers.
Suspension composition:
MedroxyprogesteroneAcetate 20%, MyristylGammaPicoliniumChloride 0.1% (batch 13451/84) or 0.2 % (batch 13451/47), sodium sulphate 1.1%, PEG 3350 2.03%, sodium hydroxide q.s. to pH 6.5 , WFI q.s to 100 ml.
Table 4a 13451/47-A13451/47-C 13451/47-G 13451/47-I
as is Phosphate Phosphate L-Methionine ~ 0.1% ~ 1% 0.5%
(0.0066 M) (0.066 M) H
Time zero 6.07 6.35 6.33 6.11 65C: 10 da 2.85 3.03 * 5.29 s 65C: 15 da 2.82 2.97 * 5.13 s ~65C: 1 month 2.88 ~ 3.06 5.13 * ~ 4.76 ~
* not resuspendable by manual wrist shaking, pH measured after mixing the suspension with a spatula Table 4b 13451/84-A13451/84-B 13451/84-C 13451/84-D
as is L-MethionineL-MethionineL-Methionine 0.1 % 0.25 % 0.1%
+
Phosphate ~ 0.1%
(0.0066M) PH
Time zero 6.10 6.04 5.94 6.31 65C: 10 da 3.00 4.49 5.28 5.92 s 65C: 15 da 2.89 4.30 4.88 6.25 s 65C: 1 month 3.01 3.83 4.55 6.20 Resus endabili 65C:1 month resuspendableresuspendableresuspendableResuspendable (15s) (13s) (15s) (14s) _ --S rin eabili 65C: 1 month meets meets test meets test ~ Meets test test Phos hate Buffers (M = molar) a rox. 0.1 a rox. 1 %
%
Monobasic Sodium Phosphate . mg 69.4 mg 694 / 100 1 H20 (MW 137.99) ! 100 ml ml (0.005 M) (0.05 M) Dibasic Sodium Phosphate . 12 mg 58.8 mg 588 / 100 H20 (MW 358.14) l 100 ml ml (0.0016 (0.016 M) M) Resuspendability: In brackets the time of manual wrist shaking requested in order to obtain a homogeneous suspension (s=seconds).
Example 3 pH stabilization of a medroxyprogesterone acetate and estradiol cypionate parenteral aqueous suspension by means of L-Methionine used alone or in combination with unconventional low amounts of phosphate buffer.
to Estradiol cypionate and medroxyprogesterone acetate is an estro-progestinic combination that is used in contraception. Both estradiol cypionate and medroxyprogesterone acetate are quite stable molecules and no relevant degradation is reported when the two actives are formulated as a parenteral aqueous suspension. In fact, rio particular stabilizers are requested to chemically stabilize the two active ingredients molecules, being the only issue to be solved is their hydrophobicity and therefore the need to use suitable wetting/suspending agents in order to obtain a re-suspendable and syringeable suspension. In the experimental trial reported in Table 5, a 1% estradiol cypionate and 5% medroxyprogesterone acetate parenteral aqueous suspension, containing suitable wetting/suspending agents has been formulated with 2o different amounts of L-Methionine and with a combination of L-Methionine and a low and unusual concentration (approx. 0.1%) of Phosphate buffer. From the data obtained, not only L-Methionine "per se" is capable to prevent the relevant pH decrease occourring to the "as is" formulation and to maintain the pH of the formulation well above 4.5 even after 1 month storage at 65°C, but, most surprisingly, when used in 5 combination with an lower and unconventional amount of phosphate buffer (approx.
0.1% or 0.0066M), the pH is stabilized to values close to the time zero value.
Besides, the stabilizing effect is similar to the one obtained by buffering the formulation with a usual effective concentration (approx. 1% or 0.066M) of phosphate buffer.
It is an advantage of this invention that the pH of certain parenteral aqueous 10 suspensions can be stabilized without buffering the formulation with a conventional buffering agents (i.e. inorganic/organic acid salts) or without usual effective concentrations of a conventional buffering agent.
As said before, the pH stabilized parenteral aqueous suspensions obtained by means of this invention do not contain conventional buffering agents or usual effective 15 concentrations of buffering agents. As a consequence, a further advantage of this invention is that the so obtained parenteral aqueous suspensions do not have buffering capacity or significant buffering capacity per se, and therefore, when injected, the pH
of the product can be more easily adjusted to the physiological value by the buffering capacity of the. tissue fluids.
2o Table 5: pH study of a 1% Estradiol Cypionate (ECP) and a 5%
Medroxyprogesterone Acetate (MPA) parenteral aqueous suspension formulated with different amount of L-Methionine and Phosphate buffers.
Suspension composition: MPA 5% , ECP 1%, methylparaben 0.18%, propylparaben 0.02%, sodium chloride 0.856%, PEG 3350 2.856%, polysorbate 80 0.19%, sodium hydroxide q.s. to pH 6.0-6.5, WFI q.s to 100 ml.
Batch 13510/01-A13510/01-B13510/01-CI3510/O1-D13510/01-E13510/01-F
as is L- L-MethionineL-MethioninePhosphateL-Methionine Methionine0.25% 0.1% ~1% 0.1%
0.5% (0.066M) + Phosphate 0.1%
(0.0066M) H
Time 6.31 6.37 6.40 6.45 6.32 6.41 zero 65C: 4.49 5.71 5.62 5.54 6.26 6.21 da s 65C: 4.29 5.69 5.46 5.40 6.33 6.25 da s 65C: 3.91 4.73 4.67 4.62 6.29 5.98 1 month --Phos hate Buffers (M = molar) A rox. 0.1 a rox. 1 %
%
Monobasic Sodium Phosphate . mg 69.4 / mg 694 / 100 1 H20 (MW 137.99) 100 ml ml (0.005 M) (0.05 M) Dibasic Sodium Phosphate . 12 mg 58.8 / mg 588 / 100 H20 (MW 358.14) 100 ml ml (0.0016 M) (0.0I6 M) The following are examples of pharmaceutical compositions according to the invention 5 and are not intended to limit the scope of the invention itself.
Example A
Stabilized Parenteral Aqueous suspension of Medroxy Progesterone Acetate.
The formulation is as follows (% wlv):
Medroxyprogesterone Acetate (micronized) 20%
Myristyl Gamma Picolinium Chloride 0.085°Io Sodium Sulphate 1.1%
Polyethylene Glycol 3350 2.03%
Polyvinylpyrrolidone K17 0.25%
Monobasic Sodium Phosphate hydrate 0.0694%
Dibasic Sodium Phosphate dodecahydrate 0.0588%
L-Methionine 0.150%
Sodium Hydroxide or Hydrochloric Acid q.s. to PH 6.0 - 7.0 Water for Injections q.s. to 100 ml to The excipients are dissolved in Water for Injections. The obtained vehicle is sterilized by steam sterilization or sterilant filtration. Sterile micronized medroxyprogesterone acetate is added to the vehicle, the obtained suspension is passed through a suitable homogenizer in aseptic condition and the pH is adjusted. The homogeneous suspension is then aseptically distributed in single-use containers.
The obtained product has desirable properties for parenteral use, keeps well and has a substantially stabilized pH.
Example B
to Stabilized Parenteral Aqueous Suspension of Medroxy Progesterone Acetate.
The formulation is as follows (% wlv):
Medroxyprogesterone Acetate 14%
Methylparaben 0.18 %
Propylparaben 0.02%
Sodium Chloride 0.8%
Polyethylene Glycol 3350 2.875%
Polysorbate 80 0.3%
Polyvinylpyrrolidone K17 0.5%
L-Methionine 0.15 %
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric PH 6.0 - 7.0 Acid q.s. to Water for Injections q.s. to 100 ml The manufacturing method includes preparation of a sterile vehicle, aseptic compounding of sterile micronized medroxyprogesterone Acetate into the vehicle and aseptic distribution of the obtained sterile homogenous suspension into single dose container.
The product has a substantially stabilized pH, good resuspendability and can be administered with a syringe-needle suitable for subcutaneous and intramuscular use.
Example C
Stabilized Parenteral Aqueous Suspension of a combination of Medroxyprogesterone Acetate and Estradyol Cypionate.
The formulation is as follows (%w/v):
Medroxyprogesterone Acetate (micronized)5%
Estradiol cypionate (micronized) 1 Methylparaben 0.180%
Propylparaben 0.020%
Sodium Chloride 0.800%
Polyethylene Glycol 3350 2.856%
Polysorbate 80 0.190%
Polyvinylpyrrolidone K17 0.250%
L-Methionine 0.150%
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric pH 6.0 - 7.0 Acid q.s. to Water for Injections q.s. to 100 ml The parabens are dissolved in Water for Injections previously heated at approximately 70-90°C. The parabens solution is cooled down to room temperature, the remaining excipients are added and dissolved and the pH is adjusted to the desired range.
Micronized medroxyprogesterone acetate and estradiol cypionate are slurried into the to vehicle and the obtained dispersion is homogenized until a fine, syringeable suspension is obtained.
In order to obtain a sterile suspension suitable for parenteral administration sterile active drugs and vehicle are used and the obtained suspension aseptically distributed into single dose containers.
IS The obtained product can be easily resuspended and can easily flow though a syringe needle, has a substantially stabilized pH and is suitable for intradermal, subcutaneous and intramuscular administration.
Example D
Stabilized Parenteral Aqueous Suspension of Exemestane.
The formulation is as follows (% w/v):
Exemestane (micronized) 10%
Methylparaben 0.18 %
Propylparaben 0.02%
Sodium Chloride 0.83%
Polyethylene Glycol 4000 3.0%
Polysorbate 80 0.2%
Methylcellulose 0.15%
Lecithin 0.5%
L-Methionine 0.1 %
Edetate disodium 0.05%
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric PH 6.0 Acid q.s. to - 7.0 Water for Injections q.s. to 100 ml Lecithin and methylcellulose are dispersed in approximately 20% of Water for Injections and the obtained dispersion autoclaved. The other excipients are dissolved in the remaining 80% of Water for Injections and the obtained solution sterilized by sterilant filtration. The two preparations are compounded in aseptic environment, the pH is adjusted and sterile exemestane is added.
The obtained suspension is passed though a suitable homogenizer until a fine, syringeable suspension is obtained and then aseptically distributed.
The product has desirable properties for parenteral use, keeps well and has a substantially stabilized pH.
controlling agent, may vary from about 0.005% w/v to about 5% w/v, preferably from about 0.01% w/v to about 1.0% w/v.
The pH controlling effective concentration of L-Methionine, when used as a combined pH controlling agent, may be substantially the same as above.
Thanks to the pH controlling properties of L-Methionine and the superadditive pH
controlling effect, which is obtainable by using L-Methionine in combination with a conventional buffering agent, the concentration of the latter can be reduced by about 50% to about 95%. Namely the concentration of the buffering agent-~an-thus range to from about 5% to about 50% of the usual buffering concentration thereof, preferably from about 5 % to about 25 %.
The usual concentrations of conventional buffering agents employed in parenteral formulations can be found in: Pharmaceutical Dosage Form: Parenteral Medications, Volume 1, 2°d Edition, Chapter 5, p. 194, De Luca and Boylan, "Formulation of Small Volume Parenterals", Table 5: Commonly used additives in Parenteral Products.
According to said literature, the usual buffering concentration for phosphoric acid salts range from about 0.8% to about 2.Oalo w/v or w/w. On the contrary, thanks to the newly found super-additive effect, the concentration of phosphoric acid salts according to the formulation of the invention are lower than 0.4% w/w or w/v, preferably lower than 0.2% w/w or w/v.
Re-suspendibility and controlled flocculation of the pharmaceutical aqueous suspension are thus improved.
The pharmaceutical aqueous suspension, according to the invention, may in addition also include one or more surfactants, suspending agents and/or thickening agents.
Suitable surfactants are for instance phospholipids (e.g. lecithin), cationic surfactants (e.g. myristylgammapicolinium chloride), anionic surfactants and non-ionic surfactants (e.g. polysorbate 80).
Suitable suspending andlor density adjusting agents are for instance polyvinylpyrrolidone compounds and polyethylene glycols. Preferred examples of 3o polyethylene glycols are those having a molecular weight from about 300 to about 6000, e.g. polyethylene glycol 3350 and polyethylene glycol 4000. Preferred polyvinylpyrrolidone (PVP) compounds according to the invention are those having a molecular weight from about 7000 to about 54000, for instance PVP K12, K17, and K30, in particular K12 and K17, PVP K17 being the most preferred.
According to a preferred embodiment of the invention, the pharmaceutical aqueous suspension formulation of the invention in addition contain a suitable amount of a PVP
compound, in particular K12 or K17, especially K17.
Suitable thickening or viscosity agents are for instance well known cellulose derivatives (e.g. methylcellulose, carboxymethylcellulose, hydroxyethylcellulose and hydroxypropylmethylcellulose), gelatin and acacia, in particular methyleellui~ose.
In addition, the formulations of the present invention may also include metal chelating agents, antioxidants or thiol-containing compounds and preservatives.
Suitable metal chelating agents are for instance ethylenediamine-tetracetic acid salts (e.g. edetate disodium).
Suitable antioxidants are for instance ascorbic acid derivatives (e.g.
ascorbic acid, erythorbic acid, sodium ascorbate), thiol derivatives (e.g. thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, dithiothreitol, gluthathione), tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, sulfurous acid salts (e.g.
sodium sulfate, sodium bisulfite, acetone sodium bisulfite, sodium metabisulfite, sodium sulfite, sodium formaldehyde sulfoxylate, sodium thiosulfate) and 2o nordihydroguaiareticacid.
Suitable preservatives are for instance phenol, chlorobutanol, benzylalcohol, methyl paraben, propyl paraben, benzalkonium chloride and cetylpyridinium chloride.
In addition; the formulations of the present invention may also include tonicity adjusting agents. Suitable tonicity adjusting agents are for instance sodium chloride, sodium sulfate, dextrose, mannitol and glycerol.
The formulations of the present invention may also have a nitrogen blanket,overlay on the head-space of the vial. Additionally, the formulations of the present invention may include purging the formulation buffer with helium, argon, or nitrogen.
When the formulation of the invention, besides L-Methionine, contains also buffering 3o agents, useful buffers include e.g. those derived from acetic, aconitic, citric, glutaric, lactic, malic, succinic, phosphate and carbonic acids, as known in the art.
Typically employed is an alkali or alkaline earth salt of one of the aforementioned acids.
Phosphate and citrate buffers, such as phosphoric acid or a pharmaceutically acceptable salt thereof, or citric acid or a pharmaceutically acceptable salt thereof, are preferred.
Sodium phosphate or sodium citrate is the preferred buffering agents, with sodium 5 phosphate being most preferred.
The pharmaceutical aqueous suspension according to the invention is e.g. for intramuscular, subcutaneous and intradermal administration, preferably for intramuscular and subcutaneous administration.
A biological active compound according to the invention is any compound that after l0 administration to a mammal, including humans, provides a therapeutic effect.
Preferably it is a steroidal biologically active compound.
A steroidal biologically active compound according to the invention is the steroidal compound itself or, when appropriate, a pharmaceutically acceptable salt thereof as known in the art, e.g. medroxyprogesterone acetate, exemestane, estradiol cypionate, methylprednisolone acetate, oxabolone cypionate, clostebol acetate, testosterone cypionate; preferably medroxyprogesterone acetate, estradiol cypionate and exemestane, or a combination of two or more thereof according to the art.
Concentrations of medroxyprogesterone acetate in the formulation can range from about 1% w/v to about 40% w/v, preferably from about 3% w/v to about 30% w/v.
2o Concentrations of estradiol cypionate in the formulation can range from about 0.1%
wlv to about 5% w/v, preferably from about 0.25% w/v to about 2.5 % w/v.
When a combination of estradiol cypionate and medroxyprogesterone acetate is the active ingredient of the pharmaceutical preparation of the invention, the amounts of such compounds present in the pharmaceutical preparation are substantially as here above.
Concentrations of exemestane in the formulation can range from about 1% wlv to about 25% w/v, preferably from about 5% wlv to about 20% w/v.
The steroidal biologically active compound is preferably in milled or micronized form according to the common practice.
3o The pH controlling activity of L-Methionine either alone or in combination with a conventional buffer is shown for instance by the following examples.
Example 1 pH stabilization of a parenteral aqueous suspension of Exemestane (CAS: 6-Methylenandrosta-1,4-dime-3,17-dione; other name: Androsta-1,4-dime-3,17-dione-methylene) by means of L-Methionine.
Exemestane is an irreversible aromatase inhibitor, structurally related to the natural steroid androstenedione and it is a molecule prone to oxidation. When performing an experimental study, by adding different antioxidants to a IO% Exemestane parenteral aqueous suspension we have surprisingly found out that L-Methionine can stabilize the pH of the suspension. In fact, the experimental data provided in Taabl~ 3 clearly to demonstrate that in the suspension formulation containing L-Methionine the pH
reduction is minimized in comparison with the "as is" and that by adding L-Methionine, the pH of the suspension is stabilized at values above pH 4.5 even after 2 months storage at 55°C.
What is outmost surprising is that among the added antioxidants, only Methionine is effective in substantially controlling/stabilizing the pH of the suspension (after 2 months storage at 55°C the pH decrease of the formulations containing ascorbic acid, and sodium metabisulfite is in fact comparable or worse than the one experimented in the "as is" formulation).
Therefore a simple antioxidant effect cannot explain the result obtained and the 2o presence of a specific stabilizer, such as L-Methionine, is needed in order to prevent a dramatic pH decrease and stabilize the parenteral aqueous suspension.
The present invention, however, is not intended to be limited to any particular theory of the exact mechanism of this substantial pH stabilization but relates to the fact that a substantial pH stabilization is obtained, to the unconventional way through which this substantial pH stabilization is obtained and to its possible advantages.
It is an advantage of the present invention that the pH of these stabilized parenteral aqueous suspensions does not dramatically decrease during storage but, on the contrary, is maintained closer to the initial value (i.e. closer to neutrality) and therefore these stabilized suspensions can be safely administered without generating significant pain on patients.
Table 3: pH study of a 10% Exemestane parenteral aqueous suspension formulation containing different antioxidants.
Suspension composition (batch 13833/11): Exemestane 10%, methylparaben 0.18%, propylparaben 0.02%, sodium chloride 0.9%, PEG 4000 3.0%, polysorbate 80 0.2%, sodium hydroxide q.s. to pH 6.0 - 6.5 , WFI q.s to 100 ml.
A: as is B: + D: E:
Ascorbic+ Sodium -1- L-Methionine Acid Metabisulfite Time zero 6.02 6.40 6.47 6.00 1 month 4.28 4.20 2.30 4 at .86 55C __ v 2 months 4.03 4.18 2.50 4.74 at Example 2 pH and technological quality (re-suspendability, syringeability) stabilization of a medroxyprogesterone acetate parenteral aqueous suspension by means of L-Methionine 1o used alone or in combination with low and unconventional concentrations of phosphate buffer.
As previously shown in Table 2, the use of a conventional buffering agent, such as Phosphate buffer, in usual effective concentrations (approx. 1%) in order to stabilize the pH of a medroxyprogesterone acetate aqueous suspension has a detrimental effect on the suspension technological quality, i.e. resuspendability and syringeability.
In this example, outlined in Table 4 (Tables 4a and 4b), it is evident that the pH of the same type of suspension can be controlled/stabilized by using L-Methionine alone or by a combination of L-Methionine with a lower and unusual concentration of phosphate buffer (approx. 0.1 %). In fact, when L-Methionine is used alone, as in the 2o case of batch 13451/47-I, a substantially stabilized pH is obtained.
Besides, when L-Methionine is used in combination with a low unusual concentration of Phosphate buffer (approx. 0.1%) a synergistic effect is obtained.
In fact, as clearly shown in the case of batch 13451/47-C, when an unusually low concentration of phosphate buffer (approx. 0.1%) is used, no significant pH
stabilization is obtained vs. the "as is" formulation.
On the contrary, when the same low unusual concentration of phosphate buffer (approx. 0.1%) is used in combination with L-Methionine, as in the case of batch 13451/84-D, a surprising super-additive effect is obtained in controlling/stabilizing the pH of the formulation.
Besides, when L-Methionine is used alone or in combination with a low unusual amount of phosphate buffer, no negative effect is produced on the suspension's technological quality, thus allowing the achievement of a pH stabilized medroxyprogesterone acetate suspension with good re-suspendability and syringeability properties that are maintained during storage. ~ w-On the contrary, when a usual effective concentration of phosphate buffer (approx. 1%) is used in order to stabilize the pH, as in the case of batch 13451/47-G, a detrimental effect on the physical stability of the formulation is obtained.
It is an advantage of this invention that the pH of parenteral aqueous suspensions can be substantially stabilized without using effective usual concentrations of conventional buffering agents, i.e. typically inorganic or organic acid salts, thus avoiding some substantial drawbacks, such as the profound effects caused by ionic species, and especially by polyvalent ions, on the nature and the stability of flocculated suspensions, with detrimental effects on suspension re-suspendability and syringeability.
Table 4: pH, resuspendability and syringeability study of a 20%
Medroxyprogesterone Acetate (MPA) parenteral aqueous suspension formulated with different amounts of L-Methionine and Phosphate buffers.
Suspension composition:
MedroxyprogesteroneAcetate 20%, MyristylGammaPicoliniumChloride 0.1% (batch 13451/84) or 0.2 % (batch 13451/47), sodium sulphate 1.1%, PEG 3350 2.03%, sodium hydroxide q.s. to pH 6.5 , WFI q.s to 100 ml.
Table 4a 13451/47-A13451/47-C 13451/47-G 13451/47-I
as is Phosphate Phosphate L-Methionine ~ 0.1% ~ 1% 0.5%
(0.0066 M) (0.066 M) H
Time zero 6.07 6.35 6.33 6.11 65C: 10 da 2.85 3.03 * 5.29 s 65C: 15 da 2.82 2.97 * 5.13 s ~65C: 1 month 2.88 ~ 3.06 5.13 * ~ 4.76 ~
* not resuspendable by manual wrist shaking, pH measured after mixing the suspension with a spatula Table 4b 13451/84-A13451/84-B 13451/84-C 13451/84-D
as is L-MethionineL-MethionineL-Methionine 0.1 % 0.25 % 0.1%
+
Phosphate ~ 0.1%
(0.0066M) PH
Time zero 6.10 6.04 5.94 6.31 65C: 10 da 3.00 4.49 5.28 5.92 s 65C: 15 da 2.89 4.30 4.88 6.25 s 65C: 1 month 3.01 3.83 4.55 6.20 Resus endabili 65C:1 month resuspendableresuspendableresuspendableResuspendable (15s) (13s) (15s) (14s) _ --S rin eabili 65C: 1 month meets meets test meets test ~ Meets test test Phos hate Buffers (M = molar) a rox. 0.1 a rox. 1 %
%
Monobasic Sodium Phosphate . mg 69.4 mg 694 / 100 1 H20 (MW 137.99) ! 100 ml ml (0.005 M) (0.05 M) Dibasic Sodium Phosphate . 12 mg 58.8 mg 588 / 100 H20 (MW 358.14) l 100 ml ml (0.0016 (0.016 M) M) Resuspendability: In brackets the time of manual wrist shaking requested in order to obtain a homogeneous suspension (s=seconds).
Example 3 pH stabilization of a medroxyprogesterone acetate and estradiol cypionate parenteral aqueous suspension by means of L-Methionine used alone or in combination with unconventional low amounts of phosphate buffer.
to Estradiol cypionate and medroxyprogesterone acetate is an estro-progestinic combination that is used in contraception. Both estradiol cypionate and medroxyprogesterone acetate are quite stable molecules and no relevant degradation is reported when the two actives are formulated as a parenteral aqueous suspension. In fact, rio particular stabilizers are requested to chemically stabilize the two active ingredients molecules, being the only issue to be solved is their hydrophobicity and therefore the need to use suitable wetting/suspending agents in order to obtain a re-suspendable and syringeable suspension. In the experimental trial reported in Table 5, a 1% estradiol cypionate and 5% medroxyprogesterone acetate parenteral aqueous suspension, containing suitable wetting/suspending agents has been formulated with 2o different amounts of L-Methionine and with a combination of L-Methionine and a low and unusual concentration (approx. 0.1%) of Phosphate buffer. From the data obtained, not only L-Methionine "per se" is capable to prevent the relevant pH decrease occourring to the "as is" formulation and to maintain the pH of the formulation well above 4.5 even after 1 month storage at 65°C, but, most surprisingly, when used in 5 combination with an lower and unconventional amount of phosphate buffer (approx.
0.1% or 0.0066M), the pH is stabilized to values close to the time zero value.
Besides, the stabilizing effect is similar to the one obtained by buffering the formulation with a usual effective concentration (approx. 1% or 0.066M) of phosphate buffer.
It is an advantage of this invention that the pH of certain parenteral aqueous 10 suspensions can be stabilized without buffering the formulation with a conventional buffering agents (i.e. inorganic/organic acid salts) or without usual effective concentrations of a conventional buffering agent.
As said before, the pH stabilized parenteral aqueous suspensions obtained by means of this invention do not contain conventional buffering agents or usual effective 15 concentrations of buffering agents. As a consequence, a further advantage of this invention is that the so obtained parenteral aqueous suspensions do not have buffering capacity or significant buffering capacity per se, and therefore, when injected, the pH
of the product can be more easily adjusted to the physiological value by the buffering capacity of the. tissue fluids.
2o Table 5: pH study of a 1% Estradiol Cypionate (ECP) and a 5%
Medroxyprogesterone Acetate (MPA) parenteral aqueous suspension formulated with different amount of L-Methionine and Phosphate buffers.
Suspension composition: MPA 5% , ECP 1%, methylparaben 0.18%, propylparaben 0.02%, sodium chloride 0.856%, PEG 3350 2.856%, polysorbate 80 0.19%, sodium hydroxide q.s. to pH 6.0-6.5, WFI q.s to 100 ml.
Batch 13510/01-A13510/01-B13510/01-CI3510/O1-D13510/01-E13510/01-F
as is L- L-MethionineL-MethioninePhosphateL-Methionine Methionine0.25% 0.1% ~1% 0.1%
0.5% (0.066M) + Phosphate 0.1%
(0.0066M) H
Time 6.31 6.37 6.40 6.45 6.32 6.41 zero 65C: 4.49 5.71 5.62 5.54 6.26 6.21 da s 65C: 4.29 5.69 5.46 5.40 6.33 6.25 da s 65C: 3.91 4.73 4.67 4.62 6.29 5.98 1 month --Phos hate Buffers (M = molar) A rox. 0.1 a rox. 1 %
%
Monobasic Sodium Phosphate . mg 69.4 / mg 694 / 100 1 H20 (MW 137.99) 100 ml ml (0.005 M) (0.05 M) Dibasic Sodium Phosphate . 12 mg 58.8 / mg 588 / 100 H20 (MW 358.14) 100 ml ml (0.0016 M) (0.0I6 M) The following are examples of pharmaceutical compositions according to the invention 5 and are not intended to limit the scope of the invention itself.
Example A
Stabilized Parenteral Aqueous suspension of Medroxy Progesterone Acetate.
The formulation is as follows (% wlv):
Medroxyprogesterone Acetate (micronized) 20%
Myristyl Gamma Picolinium Chloride 0.085°Io Sodium Sulphate 1.1%
Polyethylene Glycol 3350 2.03%
Polyvinylpyrrolidone K17 0.25%
Monobasic Sodium Phosphate hydrate 0.0694%
Dibasic Sodium Phosphate dodecahydrate 0.0588%
L-Methionine 0.150%
Sodium Hydroxide or Hydrochloric Acid q.s. to PH 6.0 - 7.0 Water for Injections q.s. to 100 ml to The excipients are dissolved in Water for Injections. The obtained vehicle is sterilized by steam sterilization or sterilant filtration. Sterile micronized medroxyprogesterone acetate is added to the vehicle, the obtained suspension is passed through a suitable homogenizer in aseptic condition and the pH is adjusted. The homogeneous suspension is then aseptically distributed in single-use containers.
The obtained product has desirable properties for parenteral use, keeps well and has a substantially stabilized pH.
Example B
to Stabilized Parenteral Aqueous Suspension of Medroxy Progesterone Acetate.
The formulation is as follows (% wlv):
Medroxyprogesterone Acetate 14%
Methylparaben 0.18 %
Propylparaben 0.02%
Sodium Chloride 0.8%
Polyethylene Glycol 3350 2.875%
Polysorbate 80 0.3%
Polyvinylpyrrolidone K17 0.5%
L-Methionine 0.15 %
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric PH 6.0 - 7.0 Acid q.s. to Water for Injections q.s. to 100 ml The manufacturing method includes preparation of a sterile vehicle, aseptic compounding of sterile micronized medroxyprogesterone Acetate into the vehicle and aseptic distribution of the obtained sterile homogenous suspension into single dose container.
The product has a substantially stabilized pH, good resuspendability and can be administered with a syringe-needle suitable for subcutaneous and intramuscular use.
Example C
Stabilized Parenteral Aqueous Suspension of a combination of Medroxyprogesterone Acetate and Estradyol Cypionate.
The formulation is as follows (%w/v):
Medroxyprogesterone Acetate (micronized)5%
Estradiol cypionate (micronized) 1 Methylparaben 0.180%
Propylparaben 0.020%
Sodium Chloride 0.800%
Polyethylene Glycol 3350 2.856%
Polysorbate 80 0.190%
Polyvinylpyrrolidone K17 0.250%
L-Methionine 0.150%
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric pH 6.0 - 7.0 Acid q.s. to Water for Injections q.s. to 100 ml The parabens are dissolved in Water for Injections previously heated at approximately 70-90°C. The parabens solution is cooled down to room temperature, the remaining excipients are added and dissolved and the pH is adjusted to the desired range.
Micronized medroxyprogesterone acetate and estradiol cypionate are slurried into the to vehicle and the obtained dispersion is homogenized until a fine, syringeable suspension is obtained.
In order to obtain a sterile suspension suitable for parenteral administration sterile active drugs and vehicle are used and the obtained suspension aseptically distributed into single dose containers.
IS The obtained product can be easily resuspended and can easily flow though a syringe needle, has a substantially stabilized pH and is suitable for intradermal, subcutaneous and intramuscular administration.
Example D
Stabilized Parenteral Aqueous Suspension of Exemestane.
The formulation is as follows (% w/v):
Exemestane (micronized) 10%
Methylparaben 0.18 %
Propylparaben 0.02%
Sodium Chloride 0.83%
Polyethylene Glycol 4000 3.0%
Polysorbate 80 0.2%
Methylcellulose 0.15%
Lecithin 0.5%
L-Methionine 0.1 %
Edetate disodium 0.05%
Monobasic Sodium Phosphate hydrate0.0694%
Dibasic Sodium Phosphate dodecahydrate0.0588%
Sodium Hydroxide or Hydrochloric PH 6.0 Acid q.s. to - 7.0 Water for Injections q.s. to 100 ml Lecithin and methylcellulose are dispersed in approximately 20% of Water for Injections and the obtained dispersion autoclaved. The other excipients are dissolved in the remaining 80% of Water for Injections and the obtained solution sterilized by sterilant filtration. The two preparations are compounded in aseptic environment, the pH is adjusted and sterile exemestane is added.
The obtained suspension is passed though a suitable homogenizer until a fine, syringeable suspension is obtained and then aseptically distributed.
The product has desirable properties for parenteral use, keeps well and has a substantially stabilized pH.
Claims (34)
1. A pharmaceutical aqueous suspension formulation for parenteral administration having a substantially stabilized pH, comprising a biologically active steroidal compound and a pH controlling effective concentration of L-Methionine, wherein the pH controlling effective concentration of L-Methionine is from about 0.005% w/v to about 5% w/v, or from about 0.005% w/w to about 5% w/w.
2. A pharmaceutical aqueous suspension formulation for parenteral administration having a substantially stabilized pH, comprising a biologically active steroidal compound, a buffering agent and L-Methionine in concentrations effective to produce a pH controlling super-additive effect.
3. A pharmaceutical composition according to claim 2, wherein the buffering agent is a phosphoric acid salt in a concentration lower than 0.4% w/v or lower than 0.4% w/w.
4. A pharmaceutical composition according to claim 3, wherein the concentration of the phosphoric acid salts is lower than 0.2% w/v or lower than 0.2% w/w.
5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the pH of the formulation is from about pH 3.0 to about pH 8Ø
6. A pharmaceutical composition according to claim 5, wherein the biologically active steroidal compound is selected from exemestane, medroxyprogesterone acetate and estradiol cypionate or a mixture of medroxyprogesterone acetate and estradiol cypionate.
7. Use of L-Methionine in the preparation of a pharmaceutical aqueous suspension formulation having substantially stabilized pH, for parenteral administration of a biologically active steroidal compound, wherein a pH
controlling effective concentration of L-Methionine is added thereto.
controlling effective concentration of L-Methionine is added thereto.
8. Use of L-Methionine and a buffering agent in concentrations effective to produce a pH controlling super-additive effect, in the preparation of a pharmaceutically aqueous suspension formulation having a substantially stabilized pH, for parenteral administration of a biologically active steroidal compound.
9. A pharmaceutical aqueous suspension formulation for parenteral administration, having a substantially stabilized pH of from about 3.0 to about 8.0, comprising:
a biologically active steroidal compound; and L-Methionine at about 0.005% w/v to about 5% w/v.
a biologically active steroidal compound; and L-Methionine at about 0.005% w/v to about 5% w/v.
10. A formulation according to claim 9, further comprising one or more of a surfactant; a suspending agent;
a thickening agent; a metal-chelating agent; an antioxidant;
a thiol-containing compound; a preservative; a tonicity-adjusting agent; or a conventional buffering agent, at about 5% to about 25%.
a thickening agent; a metal-chelating agent; an antioxidant;
a thiol-containing compound; a preservative; a tonicity-adjusting agent; or a conventional buffering agent, at about 5% to about 25%.
11. A formulation according to claim 9 or 10, wherein the L-Methionine is present at about 0.01% w/v to about 1.0% w/v.
12. A formulation according to claim 9, 10 or 11, wherein the formulation comprises a suspending agent selected from polyvinylpyrrolidone, polyethylene glycol, or a combination thereof.
13. A formulation according to claim 12, wherein the suspending agent comprises a polyethylene glycol having a molecular weight of from about 300 to about 6000.
14. A formulation according to claim 12, wherein the suspending agent comprises a polyvinylpyrrolidone having a molecular weight of from about 7000 to about 54000.
15. A formulation according to claim 14, wherein the polyvinylpyrrolidone is PVP K12 or K17.
16. A formulation according to claim 15, wherein the polyvinylpyrrolidone is PVP K17.
17. A formulation according to any one of claims 9 to 16, wherein the formulation comprises a conventional buffering agent selected from a phosphate and a citrate buffer.
18. A formulation according to claim 17, wherein the conventional buffering agent is a phosphoric acid salt at less than 0.4% w/w or less than 0.4% w/v.
19. A formulation according to claim 18, wherein the phosphoric acid salt is present at less than 0.2% w/w or less than 0.2% w/v.
20. A formulation according to claim 17, wherein the conventional buffering agent is sodium phosphate.
21. A formulation according to any one of claims 9 to 20, wherein the pH is from about 3.0 to about 7.5.
22. A formulation according to claim 21, wherein the pH is from about 4.0 to about 7Ø
23. A formulation according to any one of claims 9 to 22, wherein the steroidal compound is in milled or micronised form.
24. A formulation according to any one of claims 9 to 23, wherein the biologically active steroidal compound is selected from the group consisting of medroxyprogesterone acetate, exemestane, estradiol cypionate, methylprednisolone acetate, oxabolone cypionate, clostebol acetate and testosterone cypionate.
25. A formulation according to claim 24, wherein the biologically active steroidal compound is selected from the group consisting of medroxyprogesterone acetate, exemestane, estradiol cypionate, and a combination of two or more thereof.
26. A formulation according to claim 25, wherein the bioloigcally active steroidal compound is medroxyprogesterone acetate and is present at from about 1% w/v to about 40% w/v.
27. A formulation according to claim 26, wherein the medroxyprogesterone acetate is present at from about 3% w/v to about 30% w/v.
28. A formulation according to claim 25, wherein the biologically active steroidal compound is estradiol cypionate and is present at from about 0.1% w/v to about 5% w/v.
29. A formulation according to claim 28, wherein the estradiol cypionate is present at from about 0.25% w/v to about 2.5% w/v.
30. A formulation according to claim 25, wherein medroxyprogesterone acetate is present at from about 3% w/v to about 30% w/v, and estradiol cypionate is present at from about 0.1% w/v to about 5% w/v.
31. A formulation according to claim 25, wherein the biologically active steroidal compound is exemestane and is present at from about 1% w/v to about 25% w/v.
32. A formulation according to claim 31, wherein the exemestane is present at from about 5% w/v to about 20% w/v.
33. A formulation according to any one of claims 9 to 32 suitable for intramuscular or subcutaneous administration.
34. A vial containing a formulation according to any one of claims 9 to 33 with a nitrogen blanket overlay on the head-space of the vial.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/571,395 | 2000-05-15 | ||
| US09/571,395 US6495534B2 (en) | 2000-05-15 | 2000-05-15 | Stabilized aqueous suspensions for parenteral use |
| PCT/EP2001/004643 WO2001087266A1 (en) | 2000-05-15 | 2001-04-25 | Stabilized aqueous suspensions for parenteral use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2409059A1 CA2409059A1 (en) | 2001-11-22 |
| CA2409059C true CA2409059C (en) | 2006-04-18 |
Family
ID=24283530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002409059A Expired - Lifetime CA2409059C (en) | 2000-05-15 | 2001-04-25 | Stabilized aqueous suspensions for parenteral use |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6495534B2 (en) |
| EP (1) | EP1282402B1 (en) |
| JP (1) | JP4205341B2 (en) |
| KR (1) | KR100828957B1 (en) |
| CN (1) | CN100473376C (en) |
| AR (3) | AR029924A1 (en) |
| AT (1) | ATE313316T1 (en) |
| AU (2) | AU6737101A (en) |
| BR (1) | BR0110841A (en) |
| CA (1) | CA2409059C (en) |
| CZ (1) | CZ303872B6 (en) |
| DE (1) | DE60116084T2 (en) |
| DK (1) | DK1282402T3 (en) |
| EA (1) | EA007682B1 (en) |
| EE (1) | EE05376B1 (en) |
| ES (1) | ES2254443T3 (en) |
| HK (1) | HK1054194B (en) |
| HU (1) | HU229800B1 (en) |
| IL (2) | IL152537A (en) |
| IN (1) | IN224279B (en) |
| MX (1) | MXPA02011195A (en) |
| NO (1) | NO332215B1 (en) |
| NZ (1) | NZ522324A (en) |
| PE (1) | PE20011322A1 (en) |
| PL (1) | PL203075B1 (en) |
| SI (1) | SI1282402T1 (en) |
| SK (1) | SK287641B6 (en) |
| TW (1) | TWI256310B (en) |
| WO (1) | WO2001087266A1 (en) |
| ZA (1) | ZA200208738B (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| EP1545994B1 (en) | 2002-08-21 | 2006-11-15 | Pharmacia Corporation | Injectable pharmaceutical suspension in a two-chamber vial |
| WO2004043375A2 (en) * | 2002-11-08 | 2004-05-27 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
| RU2005133427A (en) * | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | WATERLESS SINGLE-PHASE CARRIERS AND DRUGS USING SUCH CARRIERS |
| PT1660009E (en) * | 2003-09-03 | 2015-05-18 | Miscon Trading S A | Methods for the treatment of endometriosis |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20060058390A1 (en) * | 2004-09-14 | 2006-03-16 | Molecular Therapeutics, Inc. | D-methionine formulation with improved biopharmaceutical properties |
| WO2006099121A2 (en) * | 2005-03-10 | 2006-09-21 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US20070154546A1 (en) * | 2005-12-30 | 2007-07-05 | Zhang Jack Y | Sustained release pharmaceutical compositions |
| JP2009526860A (en) * | 2006-02-15 | 2009-07-23 | ティカ レーケメデル アーベー | Stable corticosteroid mixture |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| JP5371180B2 (en) * | 2006-06-15 | 2013-12-18 | 日立コンシューマエレクトロニクス株式会社 | Projection display device |
| CA2669727C (en) * | 2006-09-27 | 2014-10-28 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| US7687516B2 (en) * | 2006-09-27 | 2010-03-30 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| US20100076019A1 (en) * | 2006-10-11 | 2010-03-25 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| GB0625962D0 (en) * | 2006-12-23 | 2007-02-07 | Renovo Ltd | Medicaments and methods for wound healing |
| CA2697160A1 (en) * | 2007-08-21 | 2009-02-26 | Harbor Biosciences, Inc. | Stabilized therapeutic compositions and formulations |
| US8287729B2 (en) * | 2008-04-28 | 2012-10-16 | California Polytechnic Corporation | Field water purification system |
| GB0813628D0 (en) * | 2008-07-25 | 2008-09-03 | Arrow Int Ltd | Stable coated anti-cancer agent |
| UY33103A (en) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | PARENTERAL PHARMACEUTICAL FORMULATION IN SUSPENSION, SUSTAINED RELEASE, IN LOW AND ULTRA LOW DOSE, IN HORMONAL THERAPY IN THE CLIMATE SYNDROME |
| EP3150702B1 (en) | 2011-06-19 | 2021-05-19 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| HUE055562T2 (en) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| UA74095U (en) * | 2012-07-20 | 2012-10-10 | Николай Иванович Гуменюк | Drug for treatment of tuberculosis |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9649353B2 (en) | 2013-09-17 | 2017-05-16 | Terapio Corporation | Methods of preventing or treating mucositis by administering RLIP76 |
| CN104706578B (en) * | 2013-12-14 | 2019-04-23 | 天津金耀集团有限公司 | A kind of preparation method of methylprednisolone acetate suspension injection composition |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9907449B2 (en) | 2015-03-16 | 2018-03-06 | Irobot Corporation | Autonomous floor cleaning with a removable pad |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017149492A1 (en) * | 2016-03-02 | 2017-09-08 | Teva Pharmaceutical Industries Ltd. | Medroxyprogesterone acetate injectable compositions and methods of use |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| BR112018070199A2 (en) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | pharmaceutical composition of steroid hormone |
| MX2018013414A (en) * | 2016-05-06 | 2019-06-06 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use. |
| US11590077B2 (en) * | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP3678637A1 (en) * | 2017-09-07 | 2020-07-15 | Teva Pharmaceutical Industries Ltd. | Medroxyprogesterone acetate injectable compositions and methods of use |
| US20200281939A1 (en) * | 2017-09-07 | 2020-09-10 | Teva Pharmaceutical Industries Ltd. | Medroxyprogesterone acetate injectable compositions and methods of use |
| IL274433B1 (en) * | 2017-11-08 | 2024-03-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| MX2020007368A (en) * | 2018-01-11 | 2020-10-12 | Viropharma Biologics Llc | Stable corticosteroid compositions. |
| WO2020049521A1 (en) * | 2018-09-07 | 2020-03-12 | Teva Pharmaceutical Industries Ltd. | Medroxyprogesterone acetate injectable compositions and methods of use |
| US10544923B1 (en) | 2018-11-06 | 2020-01-28 | Verifone, Inc. | Devices and methods for optical-based tamper detection using variable light characteristics |
| CN113316646A (en) | 2018-11-20 | 2021-08-27 | 光谱解决方案有限责任公司 | Sample collection system including sealing cap and valve |
| IT201900002857A1 (en) * | 2019-02-27 | 2020-08-27 | Ntc S R L | Process of filling containers with a powder |
| US11701094B2 (en) | 2019-06-20 | 2023-07-18 | Spectrum Solutions L.L.C. | Sample collection system including valve and plug assemblies |
| CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2022245939A1 (en) * | 2021-05-19 | 2022-11-24 | Acies Medical Llc | Point-of-use calibration system for iron ion detection system |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
| JPS5831210B2 (en) * | 1973-04-09 | 1983-07-05 | 武田薬品工業株式会社 | antennae |
| US4038389A (en) * | 1975-05-07 | 1977-07-26 | The Upjohn Company | Medroxyprogesterone acetate compositions |
| US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| JP2577744B2 (en) | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | Stable granulocyte colony-stimulating factor containing preparation |
| US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
| EP0431663B1 (en) * | 1989-12-06 | 1994-01-12 | Akzo Nobel N.V. | Stabilized solutions of psychotropic agents |
| JPH0597671A (en) | 1991-10-04 | 1993-04-20 | Sumitomo Pharmaceut Co Ltd | Lyophilized preparation for injection |
| CA2120197A1 (en) | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
| JP3862295B2 (en) * | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | Anti-obesity agent |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| JP3543144B2 (en) | 1995-03-11 | 2004-07-14 | 国際試薬株式会社 | Formulation for clinical test |
| US5780431A (en) | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
| KR100408229B1 (en) | 1996-10-04 | 2003-12-01 | 암겐 인코포레이티드 | Pharmaceutical compositions containing an mpl ligand |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
| US5880116A (en) * | 1996-12-13 | 1999-03-09 | Neurocal International | Use of celastrol to treat alzheimer's disease |
| JP3748970B2 (en) | 1997-01-31 | 2006-02-22 | 電気化学工業株式会社 | Aqueous solution containing sodium hyaluronate |
| KR100508227B1 (en) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | Aqueous suspension of loteprednol etabonate |
| EP1426058A3 (en) * | 1997-09-23 | 2004-07-28 | Dr. Rentschler Biotechnologie GmbH | Liquid interferon-beta formulations |
| US5968918A (en) * | 1997-10-17 | 1999-10-19 | Kanda; Iwao | Method for the prevention of coronary artery spasm |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| ATE254918T1 (en) | 1998-04-02 | 2003-12-15 | Akzo Nobel Nv | ORAL LIQUID SOLUTION CONTAINING THE ANTIDEPRESSANT MIRTAZAPINE |
| BR0014486A (en) | 1999-10-04 | 2002-09-17 | Chiron Corp | Pharmaceutical compositions containing stabilized liquid polypeptide |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
-
2000
- 2000-05-15 US US09/571,395 patent/US6495534B2/en not_active Expired - Lifetime
-
2001
- 2001-04-25 BR BR0110841-7A patent/BR0110841A/en not_active Application Discontinuation
- 2001-04-25 EA EA200201208A patent/EA007682B1/en not_active IP Right Cessation
- 2001-04-25 JP JP2001583735A patent/JP4205341B2/en not_active Expired - Lifetime
- 2001-04-25 DE DE60116084T patent/DE60116084T2/en not_active Expired - Lifetime
- 2001-04-25 NZ NZ522324A patent/NZ522324A/en not_active IP Right Cessation
- 2001-04-25 MX MXPA02011195A patent/MXPA02011195A/en active IP Right Grant
- 2001-04-25 AU AU6737101A patent/AU6737101A/en active Pending
- 2001-04-25 IN IN1996CH2002 patent/IN224279B/en unknown
- 2001-04-25 ES ES01945040T patent/ES2254443T3/en not_active Expired - Lifetime
- 2001-04-25 CA CA002409059A patent/CA2409059C/en not_active Expired - Lifetime
- 2001-04-25 SI SI200130485T patent/SI1282402T1/en unknown
- 2001-04-25 EP EP01945040A patent/EP1282402B1/en not_active Expired - Lifetime
- 2001-04-25 EE EEP200200631A patent/EE05376B1/en unknown
- 2001-04-25 IL IL152537A patent/IL152537A/en active IP Right Grant
- 2001-04-25 DK DK01945040T patent/DK1282402T3/en active
- 2001-04-25 CZ CZ20023750A patent/CZ303872B6/en not_active IP Right Cessation
- 2001-04-25 HU HU0302021A patent/HU229800B1/en unknown
- 2001-04-25 PL PL365793A patent/PL203075B1/en unknown
- 2001-04-25 KR KR1020027015431A patent/KR100828957B1/en active IP Right Grant
- 2001-04-25 AT AT01945040T patent/ATE313316T1/en active
- 2001-04-25 SK SK1598-2002A patent/SK287641B6/en not_active IP Right Cessation
- 2001-04-25 WO PCT/EP2001/004643 patent/WO2001087266A1/en active IP Right Grant
- 2001-04-25 AU AU2001267371A patent/AU2001267371B2/en not_active Expired
- 2001-04-25 CN CNB018095895A patent/CN100473376C/en not_active Expired - Lifetime
- 2001-05-09 TW TW090111029A patent/TWI256310B/en not_active IP Right Cessation
- 2001-05-14 PE PE2001000431A patent/PE20011322A1/en active IP Right Grant
- 2001-05-14 AR ARP010102268A patent/AR029924A1/en not_active Application Discontinuation
-
2002
- 2002-08-21 US US10/225,320 patent/US20030114430A1/en not_active Abandoned
- 2002-10-10 US US10/267,690 patent/US20030130245A1/en not_active Abandoned
- 2002-10-29 ZA ZA200208738A patent/ZA200208738B/en unknown
- 2002-11-13 NO NO20025431A patent/NO332215B1/en not_active IP Right Cessation
-
2003
- 2003-09-11 HK HK03106493.6A patent/HK1054194B/en not_active IP Right Cessation
-
2004
- 2004-12-21 IL IL16588804A patent/IL165888A0/en unknown
-
2014
- 2014-12-18 AR ARP140104760A patent/AR098830A2/en unknown
-
2018
- 2018-05-14 AR ARP180101264A patent/AR111695A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2409059C (en) | Stabilized aqueous suspensions for parenteral use | |
| AU2001267371A1 (en) | Stabilized aqueous suspensions for parenteral use | |
| Pramanick et al. | Excipient selection in parenteral formulation development | |
| US11844782B2 (en) | Aqueous composition comprising dantrolene | |
| KR20090093581A (en) | Stabilized single-phase liquid pharmaceutical compositions containing docetaxel | |
| US10278946B2 (en) | Liquid formulation of cabazitaxel | |
| CN108601730A (en) | The preparation of vancomycin | |
| US20030165568A1 (en) | Stabilized steroidal suspension | |
| SA99190968B1 (en) | Pharmaceutical compositions based on DALFOPRISTINE and QUINUPRISTINE and their preparation | |
| US7008934B2 (en) | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins | |
| EP4076442A1 (en) | Pharmaceutical composition of cyclooxygenase - 2 inhibitors | |
| WO2022034614A1 (en) | Phytonadione compositions | |
| WO2021044328A1 (en) | Cabazitaxel liquid formulations | |
| NZ773548B2 (en) | Stable intranasal formulations of carbetocin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210426 |